Background: Health-related quality of life (HRQoL) from diagnosis until end of treatment for chil-
classified as 'MRD low-risk' (undetectable MRD at induction day 29 or detectable <0.001% leukaemic cells at day 29 becoming undetectable by week 11) were randomly assigned to one (experimental arm) or two (standard therapy) blocks of 'delayed intensification' (DI) chemotherapy prior to maintenance. This additional chemotherapy comprised doxorubicin, etoposide, cyclophosphamide over a 5-day period followed by a period of neutropenia, with blood count recovery by day 21. Patients with MRD ≥ 0.001% at the end of induction were classified as 'MRD high-risk' and were randomised to continue standard therapy (Regimen A or B) or to intensify treatment further (Regimen C). There was an improvement in 5-year event-free survival to 87% in the trial overall, with no increase in relapse risk associated with de-escalation of treatment in the low-risk group 2 and a reduction in relapse risk in high-risk patients who received more intensive treatment. 3 These excellent survival outcomes raise questions about how to balance treatment-related morbidity and health-related quality of life (HRQoL). Physical side effects of chemotherapy, 4 repeated hospitalisations and associated limitations for social and physical opportunities 5 compromise a child's HRQoL.
When assessing HRQoL, a distinction is made between generic and disease-specific measures. 6 Generic measures enable comparison with the general population, while disease-specific measures focus on disease symptoms, and are considered more sensitive to evaluate different treatments. Although ratings of child HRQoL should be made by both child and parent, 7 it is often necessary to rely on parents' proxy ratings, especially where children are too young or ill to respond themselves. Parents are under intense stress given the emotional and financial costs of caring for a sick child. 8 Family care-giving burden therefore needs to be considered as an integral part of any comprehensive evaluation of HRQoL.
The aim of this study was to assess HRQoL of children treated in the UKALL 2003 trial from diagnosis until end of treatment. Parent proxy and patient reports (from children aged >8) were collected. Specifically, the following were determined: (i) generic HRQoL compared with population norms; (ii) changes in generic and disease-specific HRQoL over time, depending on child age, gender and treatment regimen; (iii) differences in HRQoL between low-risk patients randomised to treatment reduction and those receiving standard care; (iv) differences in HRQoL between high-risk patients randomised to treatment intensification and those receiving standard care. 
METHODS

From
UKALL 2003 treatment summary
Patients recruited to UKALL 2003 were initially stratified by clinical risk of relapse. Chemotherapy Regimens A (standard), B (intermediate) and C (high risk) were defined by National Cancer Institute (NCI) criteria, cytogenetics and morphological early response to treatment. 2 Standard-and intermediate-risk patients were assessed for MRD and randomised on the basis of MRD status at day 29, as described above. 
HRQoL study
Questionnaires were completed at five time points (time points 1-5, T1-T5) during scheduled clinic appointments. 
Measures and assessment strategy 2.3.1 Child's HRQoL
The PedsQL4.0 generic core 9 is a 23-item scale that yields three scores for each time point (Total, Physical and Psychosocial HRQoL). 10 Fivepoint response scales (0 = 'never a problem' to 4 = 'almost always a problem') were used for each item. Items are reverse-scored (and linearly transformed to a 0-100 scale) with higher scores indicating better HRQoL.
The PedsQL 3.0 Cancer Module 11 is a 27-item questionnaire comprising eight subscales to assess the impact of disease and treatment on pain and hurt, nausea, procedural anxiety, treatment anxiety, worry about side effects, cognitive problems, concern for appearance and communication. In order to ensure relevance to a U.K. sample, the Anglicised version of PedsQL which has been confirmed to be both valid and reliable in the U.K. population 12 was used. Questions which were also present in the PedsQL generic version were removed from the cancer module in order to reduce the overall length of the questionnaire. This resulted in a 19-item scale assessing pain and hurt, nausea, procedural anxiety, worry about side effects, concern for appearance and communication. Five-point response scales (0 = 'never a problem' to 4 = 'almost always a problem') were used, with higher scores representing worse outcomes.
Parental care-giving burden
A modified measure of parents' perceived care-giving burden in families with a child with asthma was used. 13 The resulting scale comprised 11 items asking parents how often they were bothered about specific tasks associated with their child's illness. Responses were made on 7-point Likert scales (1 = 'all of the time' to 7 = 'none of the time').
Scores were reversed so that higher scores indicated greater caregiving burden.
Questionnaires were distributed in paper version to the treatment centres and given to patients by the leukaemia specialist nurses or data 
Statistical analysis
Responses were checked for temporal consistency (that response date fell close to scheduled time point (allowing for treatment schedules at T3, and gender at T5). Responses between 2 weeks before and 6 weeks after scheduled T1 or T2, and between 3 months before and 20 weeks after scheduled T3, T4 or T5 were considered acceptable. Responses outside these ranges were excluded as were those completed after relapse or stem cell transplant. These relatively large ranges were necessary given travel times to hospitals and differences in duration between treatment regimens.
HRQoL, demographics and treatment regimens grouped by response pattern over time were measured in order to compare nonresponders with responders and detect bias related to non-response.
Phi correlations and chi-square tests were used to determine relationships between non-response at one or more time points and gender, age, initial white blood count or treatment regimen. One-sample Analyses were conducted using SPSS v21.0 and SAS v9.3 software.
Unstandardised regression coefficients (B) and significance levels of P < 0.05, P < 0.005 and P < 0.0005 are reported throughout. We used Bonferroni-corrected P-values and confidence intervals when assessing statistical significance.
RESULTS
Internal consistency reliabilities for PedsQL were acceptable at each Among eligible patients (N = 1,428), there were no demographic or clinical differences between the analysis sample (n = 874), and nonresponders (including those who returned invalid questionnaires, n = 554), P > 0.1 in each case. The groups had similar demographic profiles (responders: 55% male, median age at registration = 8 years, median white blood cell count 10 × 10 9 /l; non-responders: 59% male, median age at registration = 8 years, median white cell count 11 × 10 9 /l) and treatment regimens (responders: 41% received Regimen A, 32%
Regimen B, 27% Regimen C; non-responders: 43% Regimen A, 31%
Regimen B, 27% Regimen C).
Responses were compared for each of the 10 outcome variables between those who responded close to the due date (within 2 weeks of T1 and T2, and 6 weeks of T3, T4 and T5) with those who responded later, but within the required time frame (numbers were too small to compare those that responded earlier than expected). No differences were found between these groups for any generic or cancer-specific HRQoL subscales except that at T1, later respondents reported higher care-giving burden (mean = 3.23) than early respondents (mean = 2.64, P < 0.005) and at T2, later respondents reported less problem with nausea (mean = 0.97) than earlier respondents (mean = 1.41,
Mean scores for HRQoL subscales across time, and comparisons with norms for healthy children are shown in Table 2 . At each time point, Total, Physical and Psychosocial HRQoL scores were significantly lower than norms for healthy children.
HRQoL change over time
Physical, Psychosocial and Total HRQoL scales varied across time points (F = 397.35, P < 0.0005; F = 216.34, P < 0.0005; F = 391.37, P < 0.0005, respectively). Comparing scores at T2-T5 against the preceding time point indicated a significant decrease in generic HRQoL on each scale between T1 and T2, followed by recovery between T2 and T3. Changes in generic HRQoL between T3, T4 and T5 were positive and significant, though the degree and rates of change were smaller ( Table 2 and Fig. 2A ).
Four cancer-specific HRQoL subscales (pain and hurt, procedural anxiety, communicating about illness and worries about side effects)
showed a significant reduction between T2 and T3 before levelling between T3 and T5. Nausea increased significantly between T2 and T3 and then declined to T5. Concern for appearance showed no significant change over time (Fig. 2B ). Care-giving burden was highest at T1 and T2, followed by a rapid then gradual decrease in scores reflecting a reduction in parental burden of care over time (Fig. 2C ).
Effects of age, gender and treatment on HRQoL and change over time
There were no significant differences in generic HRQoL or caregiving burden by treatment intensity (Regimen A, B or C). However, there were treatment differences in cancer-specific HRQoL. Parents of patients receiving Regimen A reported fewer problems with pain and nausea than Regimen B (F = 7.98, P < 0.05; F = 9.32, P < 0.005, respectively). There were no significant differences between Regimen There were few gender effects, except that parents of girls consistently reported worse problems with 'concern for appearance' than parents of boys (F = 29.08, P < 0.005). Effects of gender on change over time (i.e. gender by time-point interaction) were only significant for nausea (F = 7.33, P < 0.005). There was a significant increase in nausea between T2 and T3 in boys (P < 0.005) but the increase was smaller and non-significant in girls. Conversely, nausea decreased significantly between T4 and T5 in girls (P < 0.005) but less in boys (P = NS).
Parents of older children were more likely to report that their child worried about side effects (F = 113.14, P < 0.005), and had concerns about appearance (F = 26.12, P < 0.005), but parents of younger children reported greater child procedural anxiety (F = 33.29, P < 0.005) especially at T2 (age by time-point interaction, F = 8.41, P < 0.005; age effect at T2, P < 0.005) and lessened with time. BMT, bone marrow transplant; QoL, quality of life.
TA B L E 1 Number of eligible participants remaining at each time point and number of responses received
Changes in HRQoL for patients randomised in the MRD low-and high-risk randomisations
Children with MRD low-risk (n = 521) were randomised between 1 and 2 DI and children with MRD high-risk (n = 533) were randomised between continuing on Regimen A/B and changing to Regimen C. Parents of 170 low-risk randomised children (84 with 2 DI, 86 with 1 DI) and parents of 138 high-risk randomised children (64 from Regimen A/B, 74 from Regimen C) completed HRQoL measures at least once between T3 and T5. There were no statistically significant effects of randomisation on parental care-giving burden or HRQoL, although both reduced subsample sizes and number of relevant time points should be considered when assessing these findings.
DISCUSSION
This is a large prospective study of HRQoL in children and adolescents undergoing treatment for ALL, and it provides important outcome data charting the impact on child HRQoL. Children experience highly compromised HRQoL from diagnosis and up to 2 years later confirming previous cross-sectional findings. 15 This study supports the previous study findings that children have a significant reduction in HRQoL scores across all domains. 16 One advantage of this study is the prospective design, which allows measurement over the whole treatment course demonstrating changes in HRQoL scores over time. The study also identifies important differences between younger and older children in their reactions.
The study extends previous findings that show that children treated for ALL experience very compromised HRQoL immediately after diagnosis, 15 but HRQoL improves from 3 to 6 months and 1 year after diagnosis. 17 Parent reports of child HRQoL were much lower at T2 (4 weeks after diagnosis) than pre-treatment, and parental care-giving burden levels were at their highest at T1 and T2, confirming this initial period as one of great stress for families.
Few gender differences were identified, except that parents of girls consistently reported more problems with 'concern for appearance' . These concerns among girls may be amenable to direct support and intervention throughout the treatment period. There was greater increase in nausea between T2 and T3 in boys, although there is no clear reason for this.
Parents reported that symptoms such as nausea affected all children regardless of age, but older children were more concerned about side effects and appearance than younger children. Parents reported more procedural anxiety among younger children. Significance of difference versus acutely ill children norm: one-sample t-test: *P < 0.05, **P < 0.005, ***P < 0.0005. All means are significantly different from healthy children norm at P < 0.0005 level.
TA B L E 2
Parents of children receiving Regimen A were less likely to report procedural pain and nausea than parents of those receiving Regimen B. Related problems in Regimen C patients were more similar to Regimen B. Problems with communicating effects of illness in Regimen B did not change significantly over time, whereas A and C patients had non-significantly more problems at T2, but rates dropped between T2 and T3 and thereafter remained similar to rates seen in Regimen B.
No evidence was found to support the hypothesis that one DI was associated with better HRQoL than two DI, either for the whole group or MRD low-risk patients randomised to 1 versus 2 DI, nor were hypothesised differences between patients with MRD high-risk randomised to Regimen A/B versus C evident. It is possible that the HRQoL measures were not sufficiently sensitive to detect the impact of the different treatment regimens or that there was too much variability round assessment time points, especially in the small numbers randomised in the low-and high-risk randomisations. However, results are consistent with other work suggesting that current treatments have adverse implications for HRQoL 18 and neurological functioning, 19 and these may overwhelm more subtle differences related to treatment.
There were a number of limitations to this study. Firstly, recruitment rates differed between centres, from 94% of eligible patients responding at least once to 18%. In addition, particularly at the later time points, there were a significant number of questionnaires that
were not completed and this could adversely affect the validity of the results obtained. These differences may partly reflect availability of research staff between centres. No funding was available to support recruitment. Despite this, no differences in demographic or treatment were found between patients in the study and those not, suggesting that differential recruitment rates do not challenge the integrity of the findings.
One limitation of this study is that the assessment of HRQoL at diagnosis is a retrospective judgement and may therefore be unreliable.
However, the aim was to assess the impact of therapy on HRQoL and without this measure the baseline is entirely unknown. Many patients are unwell prior to diagnosis, and this may result in parents underestimating the child's pre-illness HRQoL.
The timing of recruitment around the five data collection time points was variable, especially T3 which was affected by allocated regiment (A, B or C), treatment delays and the number of DIs. T3 and T5 were chosen to represent particular points in the treatment protocol (pre-maintenance and end of treatment), rather than an absolute time point. Variation in response time was greater than anticipated and needs to be addressed in design of future similar trials. However, these data do not suggest that longer treatment for boys compromised their HRQoL more than girls in any measurable way, at least over the period of this study.
The age range of children recruited to the HRQoL study was 4-18 years, although the main trial included younger children and those up to 25 years of age. Difficulties were experienced obtaining responses from children, especially those in the younger age range, and no single HRQoL measure is sensitive across such a broad age range. As a result, younger children were not represented, even though they represent a significant proportion of the ALL population. This is an important In addition, generic HRQoL was compared to U.S. population norms.
These norms were chosen given the extensive validation work that has been reported, 22 but may be sub-optimal for U.K. populations. The U.S. sample differs in age, sex and ethnic distribution compared to the UKALL 2003 sample, but given the way data were reported, it was impossible to allow for these differences in analysis. However, mean scores in the study population are so much lower than norms that these differences are unlikely to change the conclusions. The measure of care-giving burden was initially developed for work involving families of children with asthma. Although most items were relevant and the scale was acceptable to parents, a more specific care-giving measure might be more sensitive such as that developed by Wells et al. 23 
CONCLUSION
This prospective study demonstrates a significant impact of therapy on HRQoL for children receiving treatment for ALL. Excellent survival rates mean that it is possible to reduce treatment intensity for some patients in an attempt to improve quality of life (QoL). It is therefore vital that accurate and sensitive QoL measurement is undertaken.
Further trials are needed to confirm these findings from the perspective of the patient and to determine whether HRQoL can be enhanced by clinical or supportive interventions for patients and their families A fuller understanding of the impact of therapy on HRQoL in patients with ALL will make an important contribution to the development of patient-reported outcomes among young people.
